Opus Genetics (IRD) Total Non-Current Liabilities (2010 - 2026)
Opus Genetics (IRD) reported Total Non-Current Liabilities of $10.5 million for Q1 2026, down 56.55% year-over-year from $24.3 million in Q1 2025, and up 18.27% on a QoQ basis from $8.9 million in Q4 2025.
Opus Genetics (IRD) has 17 years of Total Non-Current Liabilities data on file, last reported at $10.5 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 56.55% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (down 56.55% YoY) and the FY2025 annual result came in at $8.9 million, down 21.12% from the prior year.
- Total Non-Current Liabilities grew to $10.5 million in Q1 2026 per IRD's latest filing, from $8.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $30.2 million in Q3 2025 and bottomed at $2.7 million in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is $4.6 million (2023), against an average of $8.2 million.
- The widest annual swing landed in 2025, when Total Non-Current Liabilities soared 395.24%; it then tumbled 56.55% in 2026.
- Tracing IRD's Total Non-Current Liabilities over 5 years: stood at $2.8 million in 2022, then surged by 44.13% to $4.0 million in 2023, then jumped by 184.65% to $11.3 million in 2024, then retreated by 21.12% to $8.9 million in 2025, then climbed by 18.27% to $10.5 million in 2026.
- Per Business Quant, the three latest IRD Total Non-Current Liabilities figures stand at $10.5 million (Q1 2026), $8.9 million (Q4 2025), and $30.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | 10.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.54 Mn |
| Dec 31, 2025 | 8.91 Mn |
| Sep 30, 2025 | 30.16 Mn |
| Jun 30, 2025 | 9.39 Mn |
| Mar 31, 2025 | 24.25 Mn |
| Dec 31, 2024 | 11.30 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 4.20 Mn |
| Mar 31, 2024 | 5.69 Mn |
| Dec 31, 2023 | 3.97 Mn |
| Sep 30, 2023 | 3.82 Mn |
| Jun 30, 2023 | 4.58 Mn |
| Mar 31, 2023 | 4.15 Mn |
| Dec 31, 2022 | 2.75 Mn |
| Sep 30, 2022 | 2.69 Mn |
| Jun 30, 2022 | 3.30 Mn |
| Mar 31, 2022 | 3.21 Mn |
| Dec 31, 2021 | 3.86 Mn |
| Sep 30, 2021 | 2.64 Mn |
| Jun 30, 2021 | 2.70 Mn |
| Mar 31, 2021 | 2.31 Mn |
| Dec 31, 2020 | 3.19 Mn |
| Sep 30, 2020 | 3.01 Mn |
| Jun 30, 2020 | 2.98 Mn |
| Mar 31, 2020 | 2.01 Mn |
| Dec 31, 2019 | 9.34 Mn |
| Sep 30, 2019 | 3.10 Mn |
| Jun 30, 2019 | 3.69 Mn |
| Mar 31, 2019 | 2.69 Mn |
| Dec 31, 2018 | 3.17 Mn |
| Sep 30, 2018 | 3.36 Mn |
| Jun 30, 2018 | 3.42 Mn |
| Mar 31, 2018 | 3.10 Mn |
| Dec 31, 2017 | 3.67 Mn |
| Sep 30, 2017 | 2.79 Mn |
| Jun 30, 2017 | 2.40 Mn |
| Mar 31, 2017 | 2.22 Mn |
| Dec 31, 2016 | 2.41 Mn |
| Sep 30, 2016 | 2.34 Mn |
| Jun 30, 2016 | 2.37 Mn |
| Mar 31, 2016 | 3.89 Mn |
| Dec 31, 2015 | 3.29 Mn |
| Sep 30, 2015 | 3.89 Mn |
| Jun 30, 2015 | 3.85 Mn |
| Mar 31, 2015 | 3.45 Mn |
| Dec 31, 2014 | 3.18 Mn |
| Sep 30, 2014 | 2.47 Mn |
| Jun 30, 2014 | 2.35 Mn |
| Mar 31, 2014 | 1.80 Mn |
| Dec 31, 2013 | 1.90 Mn |
| Sep 30, 2013 | 2.03 Mn |
| Jun 30, 2013 | 1.91 Mn |
| Mar 31, 2013 | 2.50 Mn |
| Dec 31, 2012 | 2.54 Mn |
| Sep 30, 2012 | 1.72 Mn |
| Jun 30, 2012 | 1.76 Mn |
| Mar 31, 2012 | 1.92 Mn |
| Dec 31, 2011 | 2.11 Mn |
| Sep 30, 2011 | 4.86 Mn |
| Jun 30, 2011 | 4.88 Mn |
| Dec 31, 2010 | 2.85 Mn |